6-cyano-3,4-dihydro-2,2-dimethyl-trans-3-bromo-4-hydroxy-2H-1-benzopyran | 114865-21-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 6-cyano-3,4-dihydro-2,2-dimethyl-trans-3-bromo-4-hydroxy-2H-1-benzopyran
• 英文别名: 6-cyano-trans-3-bromo-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-4-ol；trans-3-bromo-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzopyran-4-ol；3-bromo-6-cyano-2,2-dimethyl-4-hydroxychroman；(+/-)-6-cyano-3,4-dihydro-2,2-dimethyl-trans-3-bromo-4-hydroxy-2H-1-benzopyran；(+/-)-trans-3-bromo-6-cyano-3,4-dihydro-2,2-dimethyl-4-hydroxy-2H-benzopyran；2,2-dimethyl-3-bromo-6-cyano-3-4-dihydro-2H-benzo[b]pyran-4-ol；3-Bromo-4-hydroxy-2,2-dimethyl-3,4-dihydrochromene-6-carbonitrile
• CAS: 114865-21-3
• 化学式: C₁₂H₁₂BrNO₂
• 分子量: 282.137
• InChiKey: PKZZJLKUYUVLMJ-UHFFFAOYSA-N

物化性质

• 沸点：
  383.2±42.0 °C(Predicted)
• 密度：
  1.55±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-cyano-3,4-dihydro-2,2-dimethyl-trans-3-bromo-4-hydroxy-2H-1-benzopyran 在 ammonium hydroxide 、 aq. sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 (3R-trans)-4-amino-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile
  参考文献：
  名称：

  Process for preparing benzoypyranol derivatives

  摘要：

  一种制备化合物(A)的纯(3S,4R)-异构体的方法：其中取代基如下定义，吡咯烷基或哌嗪基环由将已经被分离为(3S,4R)-构型的适当前体二氢苯并吡喃醇化合物环化形成，或者(3S,4R)-构型占优势相对于(3S,4R)-构型的混合物。

  公开号：

  US05126460A1
• 作为产物：
  描述：

  2,2-二甲基-2H-1-苯并吡喃-6-甲腈 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 水 为溶剂， 生成 6-cyano-3,4-dihydro-2,2-dimethyl-trans-3-bromo-4-hydroxy-2H-1-benzopyran
  参考文献：
  名称：

  [EN] COMPOSITIONS AND METHODS FOR EXTENDED RELEASE CROMAKALIM THERAPY
  [FR] COMPOSITIONS ET PROCÉDÉS POUR UNE THÉRAPIE PAR CROMAKALIM À LIBÉRATION PROLONGÉE

  摘要：

  Extended-release pharmaceutical compositions comprising a biodegradable microparticle, nanoparticle or other polymeric formulation of Formula I, Formula II, or Formula III or a pharmaceutically acceptable salt thereof are provided with advantageous properties for in vivo delivery to a patient in need thereof. The extended-release formulations overcome historic obstacles in cromakalim, including levcromakalim, delivery.

  公开号：

  WO2023018958A1

文献信息

• Benzopyrans
  申请人：Beecham Group p.l.c.

  公开号：US04446113A1

  公开（公告）日：1984-05-01

  Compounds of formula (I): ##STR1## wherein: one of R.sub.1 and R.sub.2 is hydrogen and the other is selected from the class of alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, alkylsulphinyl, alkylsulphonyl, alkoxysulphinyl, alkoxysulphonyl, alkylcarbonylamino, alkoxycarbonylamino, or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two alkyl groups, or alkylsulphinylamino, alkylsulphonylamino, alkoxysulphinylamino or alkoxysulphonylamino, or ethylenyl terminally substituted by alkylcarbonyl, nitro or cyano or --C(alkyl)NOH or --C(alkyl)NNH.sub.2, the alkyl groups or alkyl moieties of alkyl-containing groups having from 1 to 6 carbon atoms; one of R.sub.3 and R.sub.4 is hydrogen or alkyl having from 1 to 4 carbon atoms and the other is alkyl having from 1 to 4 carbon atoms, or R.sub.3 and R.sub.4 together with the carbon atom to which they are attached are spiroalkyl having from 3 to 6 carbon atoms; R.sub.5 is hydrogen, alkyl having from 1 to 3 carbon atoms or acyl having from 1 to 8 carbon atoms; and n is 1 or 2; the lactam group being trans to the OR.sub.5 group; have anti-hypertensive activity and are of use in the treatment of high blood pressure.

  式（I）的化合物：其中：R.sub.1和R.sub.2中的一个是氢，另一个选自烷基羰基、烷氧羰基、烷基羟基甲基、硝基、氰基、氯基、三氟甲基、烷基砜基、烷基磺酰基、烷氧基砜基、烷氧基磺酰基、烷基羰胺基、烷氧羰胺基，或氨基砜基、氨基磺酰基或氨基羰基类别，氨基团可选地被一个或两个烷基基团取代，或者烷基砜基氨基、烷基磺酰基氨基、烷氧基砜基氨基或烷氧基磺酰基氨基，或者末端取代为烷基羰基、硝基或氰基或--C（烷基）NOH或--C（烷基）NNH.sub.2的乙烯基，烷基含有1至6个碳原子的烷基基团；R.sub.3和R.sub.4中的一个是氢或含有1至4个碳原子的烷基，另一个是含有1至4个碳原子的烷基，或者R.sub.3和R.sub.4与它们连接的碳原子一起是含有3至6个碳原子的螺环烷基；R.sub.5是氢、含有1至3个碳原子的烷基或含有1至8个碳原子的酰基；n为1或2；内酰胺基团位于OR.sub.5基团的反位；具有降压活性，并可用于治疗高血压。
• Chromanol derivatives, a process for their preparation and pharmaceutical compositions comprising them
  申请人：BEECHAM GROUP PLC

  公开号：EP0009912A1

  公开（公告）日：1980-04-16

  Compounds of the formula (I): wherein the pyrrolidino and OR moieties are trans and wherein R is a hydrogen atom an alkyl group of 1 to 3 carbon atoms or an acyl group of 1 to 8 carbon atoms; or a pharmaceutically acceptable acid addition salt thereof; are anti-hypertensive agents. Their preparation and formulation is described.

  式(I)化合物： 其中吡咯烷基和 OR 基为反式，R 为氢原子、1 至 3 个碳原子的烷基或 1 至 8 个碳原子的酰基；或其药学上可接受的酸加成盐；是抗高血压药物。本文介绍了它们的制备和配方。
• Novel chromenes and chromans
  申请人：BEECHAM GROUP PLC

  公开号：EP0093535A1

  公开（公告）日：1983-11-09

  Compounds of formula (I): wherein: either one of R1 and R2 is hydrogen and the other is selected from the class of C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonyloxy, C1-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C1-6 alkylsulphinyl, C1-6 alkylsulphonyl, C1-6 alkoxysulphinyl, C1-6 alkoxysulphonyl, C1-6 alkylcarbonylamino, C1-6 alkoxycarbonylamino, C1-6 alkyl-thiocarbonyl, C1-6 alkoxy-thiocarbonyl, C1-6 alkyl-thiocarbonyloxy, C1-6 alkyl-thiolmethyl, formyl or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C1-6 alkyl groups, or C1-6 alkylsulphinylamino, C1-6 alkylsulphonylamino C1-6 alkoxysulphinylamino or C1-6 alkoxysulphonylamino or ethylenyl terminally substituted by C1-6 alkylcarbonyl, nitro or cyano, or -C(C1-6 alkyl)NOH or -C(C1-6 alkyl)NNH2, or one of R1 and R2 is nitro, cyano or C1-3 alkylcarbonyl and the other is methoxy or amino optionally substituted by one or two C1-3 alkyl or by C2-7 alkanoyl; one of R3 and R4 is hydrogen or C1-4 alkyl and the other is C1-4 alkyl or R3 and R4 together are C2-5 polymethylene; X is oxygen or sulphur; Y and Z are each hydrogen or together represent a bond; n is 1 or 2; or when one or the other of R, and R2 is an amino or an amino-containing group, a pharmaceutically acceptable salt thereof, having anti-hypertensive activity.

  式(I)化合物： 其中 R1 和 R2 中的任一个为氢，另一个选自 C1-6 烷基羰基、C1-6 烷氧基羰基、C1-6 烷基羰氧基、C1-6 烷基羟甲基、硝基、氰基、氯基、三氟甲基、C1-6 烷基亚磺酰基、C1-6 烷基磺酰基、C1-6 烷氧基磺酰基、C1-6 烷基羰基、C1-6 烷氧基磺酰基、C1-6 烷基羰基C1-6烷基磺酰基、C1-6烷氧基磺酰基、C1-6烷氧基磺酰基、C1-6烷基羰基氨基、C1-6烷氧基羰基氨基、C1-6烷基硫代羰基、C1-6烷氧基硫代羰基、C1-6烷基硫代羰氧基、C1-6烷基硫醇甲基、甲酰基或氨基磺酰基、氨基磺酰基或氨基羰基，氨基可选择被一个或两个 C1-6 烷基取代，或 C1-6 烷基亚磺酰氨基、C1-6 烷基磺酰基氨基、C1-6 烷氧基亚磺酰基氨基或 C1-6 烷氧基磺酰基氨基或乙烯基最终被 C1-6 烷基羰基取代、硝基或氰基，或-C(C1-6 烷基)NOH 或-C(C1-6 烷基)NNH2，或 R1 和 R2 中的一个是硝基、氰基或 C1-3 烷基羰基，另一个是甲氧基或被一个或两个 C1-3 烷基或 C2-7 烷酰基任选取代的氨基； R3 和 R4 中的一个是氢或 C1-4 烷基，另一个是 C1-4 烷基，或 R3 和 R4 合在一起是 C2-5 聚亚甲基； X 是氧或硫 Y和Z各自为氢或共同代表一个键； n为1或2；或当R和R2中的一个或另一个为氨基或含氨基的基团时，其为具有抗高血压活性的药学上可接受的盐。
• Pharmaceutically active aminobenzopyrans
  申请人：BEECHAM GROUP PLC

  公开号：EP0095316A1

  公开（公告）日：1983-11-30

  Compounds of formula (I): wherein: either one of R, and R2 is hydrogen and the other is selected from the class of C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonyloxy, C1-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C1-6 alkylsulphinyl, C1-6 alkylsulphonyl, C1-6 alkoxysulphinyl, C1-6 alkoxysulphonyl, C1-6 alkylcarbonylamino, C1-6 alkoxycarbonylamino, C1-6 alkyl- thiocarbonyl, C1-6 alkoxy-thiocarbonyl, C1-6 alkyl- thiocarbonyloxy, C1-6 alkyl-thiolmethyl, formyl or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C1-6 alkyl groups, or C1-6 alkylsulphinylamino, C1-6 alkylsulphonylamino C1-6 alkoxysulphinylamino or C1-6 alkoxysulphonylamino or ethylenyl terminally substituted by C1-6 alkylcarbonyl, nitro or cyano, or -C(C1-6 alkyl)NOH or -C(C1-6 alkyl)NNH2, or one of R, and R2 is nitro, cyano or C1-3 alkylcarbonyl and the other is methoxy or amino optionally substituted by one or two C1-6 alkyl or by C2-7 alkanoyl; one of R3 and R4 is hydrogen or C1-4 alkyl and the other is C1-4 alkyl or R3 and R4 together with the carbon atom to which they are attached are C2-5 polymethylene; either Rs is hydroxy, C1-6 alkoxy or C2-7 acyloxy and R6 is hydrogen or R5 and R6 together are a bond; R7 is hydrogen, C1-6 alkyl optionally substituted by hydroxy, C1-6 alkoxy, C1-6 alkoxycarbonyl or carboxy, or C1-2 alkyl substituted by halogen, or C2.6 alkenyl; R8 is hydrogen or C1-6 alkyl; and X is oxygen or sulphur; the Re-N-CX-R7 group being trans to the R5 group when R5 and R6 together are not a bond; or, when one or the other of R, and R2 is an amino or an amino-containing group, a pharmaceutically acceptable salt thereof, having anti-hypertensive activity.

  式(I)化合物： 其中 R 和 R2 中的任一个是氢，另一个选自 C1-6 烷基羰基、C1-6 烷氧基羰基、C1-6 烷基羰氧基、C1-6 烷基羟甲基、硝基、氰基、氯基、三氟甲基、C1-6 烷基亚磺酰基、C1-6 烷基磺酰基、C1-6 烷氧基磺酰基、C1-6 烷基羰基、C1-6 烷氧基磺酰基、C1-6 烷基羰基C1-6烷基磺酰基、C1-6烷氧基磺酰基、C1-6烷氧基磺酰基、C1-6烷基羰基氨基、C1-6烷氧基羰基氨基、C1-6烷基硫代羰基、C1-6烷氧基硫代羰基、C1-6烷基硫代羰氧基、C1-6烷基硫醇甲基、甲酰基或氨基磺酰基、氨基磺酰基或氨基羰基，氨基可选择被一个或两个 C1-6 烷基取代，或 C1-6 烷基亚磺酰氨基、C1-6 烷基磺酰基氨基、C1-6 烷氧基亚磺酰基氨基或 C1-6 烷氧基磺酰基氨基或乙烯基最终被 C1-6 烷基羰基取代、硝基或氰基，或-C(C1-6 烷基)NOH 或-C(C1-6 烷基)NNH2，或 R 和 R2 中的一个是硝基、氰基或 C1-3 烷基羰基，另一个是甲氧基或被一个或两个 C1-6 烷基或 C2-7 烷酰基任选取代的氨基； R3 和 R4 中的一个是氢或 C1-4 烷基，另一个是 C1-4 烷基，或者 R3 和 R4 连同它们所连接的碳原子是 C2-5 聚亚甲基； Rs 为羟基、C1-6 烷氧基或 C2-7 乙酰氧基，R6 为氢，或 R5 和 R6 合在一起为键； R7 是氢、任选被羟基、C1-6 烷氧基、C1-6 烷氧羰基或羧基取代的 C1-6 烷基，或被卤素取代的 C1-2 烷基，或 C2.6 烯基； R8 是氢或 C1-6 烷基；以及 X是氧或硫；当R5和R6合在一起不是键时，Re-N-CX-R7基团反式为R5基团；或者，当R和R2中的一个或另一个是氨基或含氨基的基团时，其为药学上可接受的盐，具有抗高血压活性。
• 3,4-Dihydro-thiaoxo-1-pyrrolidinyl-or piperidinyl-ZH-benzo[b]pyrons
  申请人：BEECHAM GROUP PLC

  公开号：EP0120427A1

  公开（公告）日：1984-10-03

  A compound of formula (I): wherein: either one of Ri and R2 is hydrogen and the other is selected from the class of C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonyloxy, C1-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C1-6 alkylsulphinyl, C1-6 alkylsulphonyl, C1-6 alkoxysulphinyl, Ci-6 alkoxysulphonyl, C1-6 alkylcarbonylamino, C1-6 alkoxycarbonylamino, C1-6 alkyl-thiocarbonyl, C1-6 alkoxy-thiocarbonyl, C1-6 alkyl-thiocarbonyloxy, 1-mercapto-C2-7 alkyl, formyl or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C1-6 alkyl groups, or C1-6 alkysulphinylamino, C1-6 alkylsulphonylamino C1-6 alkoxysulphinylamino or C1-6 alkoxysulphonylamino or ethylenyl terminally substituted by C1-6alkylcarbonyl, nitro or cyano, or -C(C1-6alkyl) NOH or -C(C1-6alkyl) N NH2, or one of R1 and R2 is nitro, cyano or Ci-3 alkylcarbonyl and the other is methoxy or amino optionally substituted by one or two C1-6 alkyl groups or by C2-7alkanoyl; one or R3 and R4 is hydrogen or C1-4 alkyl and the other is C1-4 alkyl or R3 and R4 together are C2-5 polymethylene. Rsis hydrogen, C1-3 alkyl or C1-8acyl; and n is 1 or 2; the thiolactam group being trans to the ORs group; or, when one orthe other of R1 and R2 is an amino or an amino-containing group capable of forming an acid addition salt, a pharmaceutically acceptable saltthereof, having useful pharmacological activity, a process for preparing them, pharmaceutical compositions containing them, and their use in the treatment of mammals.

  式(I)化合物： 其中 Ri 和 R2 中的任一个是氢，另一个选自 C1-6 烷基羰基、C1-6 烷氧基羰基、C1-6 烷基羰氧基、C1-6 烷基羟甲基、硝基、氰基、氯基、三氟甲基、C1-6 烷基亚磺酰基、C1-6 烷基磺酰基C1-6烷基硫醚基、C1-6烷基磺酰基、Ci-6烷氧基磺酰基、C1-6烷基羰基氨基、C1-6烷氧基羰基氨基、C1-6烷基硫代羰基、C1-6烷氧基硫代羰基、C1-6烷基硫代羰氧基、1-巯基-C2-7烷基、甲酰基或氨基磺酰基、氨基磺酰基或氨基羰基、氨基可任选被一个或两个 C1-6 烷基取代，或被 C1-6 烷基亚磺酰氨基、C1-6 烷基磺酰氨基、C1-6 烷氧基亚磺酰氨基或 C1-6 烷氧基磺酰氨基或乙烯基最终被 C1-6 烷基羰基取代、硝基或氰基，或-C(C1-6烷基) NOH或-C(C1-6烷基) N NH2，或R1和R2中的一个是硝基、氰基或Ci-3烷基羰基，另一个是甲氧基或被一个或两个C1-6烷基或C2-7烷酰基任选取代的氨基； R3 和 R4 中的一个是氢或 C1-4 烷基，另一个是 C1-4 烷基，或 R3 和 R4 合在一起是 C2-5 聚亚甲基。 R1和R2中的一个或另一个是能形成酸加成盐的氨基或含氨基的基团时，则是其药学上可接受的盐，具有有用的药理活性，制备它们的工艺，含有它们的药物组合物，以及它们在治疗哺乳动物中的用途。